MINNEAPOLIS (May 12, 2017) – National Women’s Health Week (May 14-20) is an important annual reminder for women to prioritize their health. Fortunately, a new area of personalized medicine called pharmacogenomics is helping women avoid and treat many top health issues. OneOme’s RightMed® pharmacogenomic test uses the power of DNA to predict which medications may work best for an individual patient – helping women avoid adverse drug reactions and better treat conditions including heart disease and cancer.

MINNEAPOLIS (May 08, 2017) – Minneapolis-based pharmacogenomics company OneOme today announced it has earned a 2017 Eureka Innovation Award from the Minneapolis / St. Paul Business Journal. The Eureka Innovation awards recognize game-changing companies across Minnesota industries. OneOme earned this recognition due to its groundbreaking product that brings routine pharmacogenomic testing into medical clinics around the world, and integrates results into the patient’s medical record for years of more accurate, personalized prescriptions.

MINNEAPOLIS (April 19, 2017) – Tomorrow, OneOme’s director of medical affairs Josiah Allen will join the Minnesota Health Care Roundtable on precision medicine. The panel, which includes local leaders in the field, takes place on Thursday, April 20, from 1 to 4 p.m. at the Downtown Minneapolis Hilton and Towers. The roundtable discussion aims to explore how technological and policy advancements can promote more precise medical treatments to improve health.

MinnPost published an article recounting the story of how OneOme’s RightMed pharmacogenomic test helped identify an effective prescription treatment for a teenager struggling with mental health conditions.

MINNEAPOLIS (March 27, 2017) – Pharmacogenomics company OneOme today announced the results of its clinician pharmacogenomic testing awareness survey. OneOme will formally share its findings at the Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting, which begins March 27 in Denver. OneOme’s poster, Strategies for increasing clinician awareness of pharmacogenomic testing, will be presented on March 28, 2017 from 5:45-7:30 p.m.

MINNEAPOLIS (March 27, 2017) – Pharmacogenomics company OneOme today announced the results of its clinician pharmacogenomic testing awareness survey. OneOme will formally share its findings at the Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting, which begins March 27 in Denver. OneOme’s poster, Strategies for increasing clinician awareness of pharmacogenomic testing, will be presented on March 28, 2017 from 5:45-7:30 p.m.

Imbio, LLC, a medical imaging software company, has closed on $1.5 million in Series A financing. Existing investor Invenshure, LLC, led the round with additional funding from several angel investors. The proceeds will support the commercialization of Imbio’s proprietary Parametric Response Mapping (PRM) technology used to detect, characterize and quantify abnormal tissue in computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) images.

MINNEAPOLIS (March 21, 2017) – OneOme continues to make strides to ensure its powerful pharmacogenomics testing is a lasting tool for patients and healthcare providers. Results from OneOme’s RightMed test, which analyzes an individual’s DNA to predict his or her response to medications, now can be integrated into a patient’s Electronic Medical Record (EMR). Since a patient’s DNA does not change over time, the results can serve as a lifelong resource for making effective prescription decisions.

MINNEAPOLIS (March 13, 2017) – OneOme today announced that healthcare providers now are able to order OneOme’s RightMed® pharmacogenomic test as part of an ordinary blood panel. Previously, the RightMed test was only available through a cheek swab. Making testing available using blood will further bring pharmacogenomic testing – the analysis of how a patient’s unique DNA affects their response to medications – into routine clinical care.

MINNEAPOLIS (Feb. 2, 2017) — OneOme, a pharmacogenomics company, announced today it has been selected to present at the ninth Cavendish Global Health Impact Forum taking place February 6-8, 2017 in San Diego, California. The Forum provides an environment for family offices, foundations and impact investors to develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, impact investors, research institutions, private-sector companies and nonprofit organizations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of impact investors, Cavendish Impact Forums are hosted by leading institutions around the world and take place four times each year.

MINNEAPOLIS (Feb. 1, 2017) – This Heart Month, people suffering from heart conditions have a new opportunity to improve the effectiveness of their cardiovascular treatments through their healthcare provider: OneOme’s RightMed pharmacogenomic test. The RightMed test uses the power of DNA to minimize medication trial and error by determining which heart medications may work best for an individual patient.

MINNEAPOLIS (Jan. 26, 2017) – Pharmacogenomics company OneOme announced today that Jason Ross will serve as its chief technology officer and that Josiah Allen was promoted to OneOme’s director of medical affairs.

“We are glad to add Josiah Allen and Jason Ross to our leadership team,” said Paul Owen, CEO of OneOme. “OneOme is on the cutting edge of making prescriptions personal, and Josiah and Jason bring the medical and technological expertise to make that dream a reality.”

MINNEAPOLIS, January 24, 2017 – Venture catalyst Invenshure announces the move of its corporate offices from the Warehouse District in Northeast Minneapolis. The company now occupies the entire SW corner of the 3rd floor of the Highlight Center building off Broadway. Buildout began last September (2016) and the move was completed in early December.

MINNEAPOLIS (Jan. 10, 2017) – Pharmacogenomics company OneOme today announced the U.S. Patent and Trademark office has issued “Patent Pending” status for its RightMed pharmacogenomic test and RightMed Advisor, an online tool for providers to quickly and easily interpret test results and gain access to an expert pharmacogenomic knowledge base.

MINNEAPOLIS (Jan. 9, 2017) – Twin Cities-based pharmacogenomics company OneOme announced today that it has earned laboratory certification in California, Florida, Maryland, Pennsylvania, and Rhode Island. These certifications affirm OneOme’s commitment to exceeding the specific clinical laboratory testing and quality standards required by these five states. OneOme will immediately begin accepting orders from these states for its RightMed® pharmacogenomic test, which analyzes a patient’s genetic profile to determine whether certain medications might be effective for that patient.

CEOCFO Magazine, a “weekly publication featuring in-depth interviews with many of today’s top corporate executives,” recently published an interview with Paul Owen, CEO of OneOme.

In the interview Paul discusses the OneOme RightMed® pharmacogenomic test, an analysis of individual patients’ genetic information to help providers make better prescription decisions. Owen provides insight into the benefits of the test, the science behind the test, and the past and future of OneOme’s success.

NEW YORK (GenomeWeb) – After more than a year building its business as a provider of pharmacogenomic data interpretation, PGx firm OneOme has now expanded with the launch of its own genetic test, a PCR-based panel covering 22 genes related to hundreds of drugs.

Download full article

Waconia, Minn. (Dec. 5, 2016) – Driven to continually improve patient care, Ridgeview Medical Center today announced a partnership with Twin Cities-based pharmacogenomics company OneOme, developer of the RightMed test. Through this partnership, Ridgeview patients will have an opportunity to receive personalized prescription treatment options.

MINNEAPOLIS (Nov. 29, 2016) – A Minnesota company today announced it has launched an innovative physician-ordered test for identifying which medications may work best for individual patients. OneOme, a growing pharmacogenomics company, has introduced the RightMed test, making it possible for physicians to quickly and accurately personalize medications for individual patients – even before they take the first dose.

November 28, 2016 – CHICAGO–(BUSINESS WIRE)–NTT DATA Services, formerly Dell Services, today announced its partnership with Imbio, which will provide algorithms for lung analytics. The algorithms are designed to further enhance automated tools for assisting radiology in identifying and quantifying disease present in existing and new imaging studies. The algorithms from Imbio provide for fully-automated quantification and visualization of lung structure, which is key to personalized diagnosis, surgical planning and therapy response monitoring. The Unified Clinical Archive (UCA) services from NTT DATA Services include a universal imaging analytics solution that supports machine vision and neural networks to more rapidly identify the extent of disease and accelerate the identification of incidental findings for early detection of potential chronic disease.